Authors
1 Applied Physiology Research Center, Isfahan, Iran
2 Department of Basic Sciences, Payame Noor University, Shahin Shahr Branch, Isfahan, Iran
3 Department of Physiology, School of Medicine; Biosensor Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Applied Physiology Research Center; Department of Physiology, School of Medicine, Isfahan, Iran
Abstract
Background: Studies have shown that Doxepin has anti-inflammatory effects and reduces oxidative stress. Due to the fact that other tricyclic antidepressants have been shown to have neuroprotective effects, this study aimed to investigate the effects of different doses of doxepin on passive avoidance learning in rats.
Materials and Methods: Old male Wistar rats were used in this study. Doxepin was administered intraperitoneally (1, 5 and 10 mg/kg) for 21 days. Passive avoidance learning test was used for evaluation of learning and memory. Rats received foot electrical shock on fifteen day, and step through latencies were evaluated one week after the electrical shock in retention phase.
Results: Administration of Doxepin considerably increased the step through latencies in the rats that received the doses of 1 and 5 mg/kg ( P < 0.05). However, in the dose of 10 mg/kg, there wasn't any significant change comparing to control group.
Conclusion: These results indicate that Doxepin has desirable effects on cognitive functions in low doses. Therefore, Doxepin can be considered as memory enhancers that understanding the underling mechanisms need further investigation.
Keywords
1. | Roumestan C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C, et al. Anti-inflammatory properties of desipramine and fluoxetine. Respir Res 2007;8:35. [PUBMED] |
2. | Xu H, Steven Richardson J, Li XM. Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 2003;28:53-62. [PUBMED] |
3. | Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999;46:1181-91. [PUBMED] |
4. | Watanabe Y, Gould E, Daniels DC, Cameron H, McEwen BS. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol 1992;222:157-62. [PUBMED] |
5. | Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201-17. [PUBMED] |
6. | Abdel-Salam OM, Baiuomy AR, Arbid MS. Studies on the anti-inflammatory effect of fluoxetine in the rat. Pharmacol Res 2004;49:119-31. [PUBMED] |
7. | Bianchi M, Sacerdote P, Panerai AE. Chlomipramine differently affects inflammatory edema and pain in the rat. Pharmacol Biochem Behav 1994;48:1037-40. [PUBMED] |
8. | Manderbacka K, Sund R, Koski S, Keskimaki I, Elovainio M. Diabetes and depression? Secular trends in the use of antidepressants among persons with diabetes in Finland in 1997-2007. Pharmacoepidemiol Drug Saf 2011;20:338-43. |
9. | Zautra AJ, Yocum DC, Villanueva I, Smith B, Davis MC, Attrep J, et al. Immune activation and depression in women with rheumatoid arthritis. J Rheumatol 2004;31:457-63. [PUBMED] |
10. | Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: A systematic review and meta-analysis. Diabet Med 2006;23:1165-73. [PUBMED] |
11. | Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31. |
12. | Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 2002;16:569-74. [PUBMED] |
13. | Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000;20:9104-10. [PUBMED] |
14. | Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009;87:1037-45. [PUBMED] |
15. | Jin Y, Lim CM, Kim SW, Park JY, Seo JS, Han PL, et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 2009;1281:108-16. [PUBMED] |
16. | Jacobson MD, Raff MC. Programmed cell death and Bcl-2 protection in very low oxygen. Nature 1995;374:814-6. [PUBMED] |
17. | Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Annu Rev Neurosci 1997;20:245-67. [PUBMED] |
18. | Chen DF, Schneider GE, Martinou JC, Tonegawa S. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 1997;385:434-9. [PUBMED] |
19. | Gajdosik A, Gajdosikova A, Stefek M, Navarova J, Hozova R. Streptozotocin-induced experimental diabetes in male Wistar rats. Gen Physiol Biophys 1999;18:54-62. |
20. | Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, et al. Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001;62:453-63. [PUBMED] |
21. | Sun XY, Zhang L, Wei CX, Piao HR, Quan ZS. Characterization of the anticonvulsant activity of doxepin in various experimental seizure models in mice. Pharmacol Rep 2009;61:245-51. [PUBMED] |
22. | Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol 1994;31:613-6. [PUBMED] |
23. | Ray SK, Fidan M, Nowak MW, Wilford GG, Hogan EL, Banik NL. Oxidative stress and Ca 2+ influx upregulate calpain and induce apoptosis in PC12 cells. Brain Res 2000;852:326-34. [PUBMED] |
24. | Ji BS, Ji H, Liu GQ. Doxepin protects cultured neurons against oxidative stress-induced injury. Acta Pharmacol Sin 2004;25:297-300. [PUBMED] |
25. | Di Napoli M, Shah IM. Neuroinflammation and cerebrovascular disease in old age: A translational medicine perspective. J Aging Res 2011;2011:857484. [PUBMED] |
26. | Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, et al. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 2011;32:1390-7. [PUBMED] |
27. | Keeney JT, Swomley AM, Harris JL, Fiorini A, Mitov MI, Perluigi M, et al. Cell cycle proteins in brain in mild cognitive impairment: Insights into progression to Alzheimer disease. Neurotox Res 2012;22:220-30. [PUBMED] |
28. | Reeta KH, Mehla J, Gupta YK. Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats. Eur J Pharmacol 2010;644:106-12. [PUBMED] |
29. | Harman D. Aging: A theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300. [PUBMED] |
30. | Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov 2009;3:73-80. [PUBMED] |
31. | Oxenkrug G. Interferon-gamma-Inducible Inflammation: Contribution to Aging and Aging-Associated Psychiatric Disorders. Aging Dis 2011;2:474-86. [PUBMED] |
32. | Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol 2007;147:227-35. [PUBMED] |
33. | Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010;140:918-34. [PUBMED] |
34. | Lunnon K, Teeling JL, Tutt AL, Cragg MS, Glennie MJ, Perry VH. Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol 2011;186:7215-24. [PUBMED] |
35. | Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med 2009;71:171-86. [PUBMED] |
36. | Chung YC, Kim SR, Jin BK. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010;185:1230-7. [PUBMED] |
37. | Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, Corser B, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007;30:1555-61. [PUBMED] |
38. | Lankford A, Rogowski R, Essink B, Ludington E, Heith Durrence H, Roth T. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 2012;13:133-8. [PUBMED] |
39. | Ferrara M, Moroni F, De Gennaro L, Nobili L. Hippocampal sleep features: Relations to human memory function. Front Neurol 2012;3:57. [PUBMED] |
40. | Wright KP, Lowry CA, Lebourgeois MK. Circadian and wakefulness-sleep modulation of cognition in humans. Front Mol Neurosci 2012;5:50. [PUBMED] |
41. | Saletin JM, Walker MP. Nocturnal mnemonics: Sleep and hippocampal memory processing. Front Neurol 2012;3:59. [PUBMED] |
42. | Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, et al. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2010;332:505-14. [PUBMED] |
43. | Chadwick W, Mitchell N, Caroll J, Zhou Y, Park SS, Wang L, et al. Amitriptyline-mediated cognitive enhancement in aged 3xTg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PLoS One 2011;6:e21660. [PUBMED] |
44. | Melanson SE, Lewandrowski EL, Griggs DA, Flood JG. Interpreting tricyclic antidepressant measurements in urine in an emergency department setting: Comparison of two qualitative point-of-care urine tricyclic antidepressant drug immunoassays with quantitative serum chromatographic analysis. J Anal Toxicol 2007;31:270-5. [PUBMED] |
45. | Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, et al. Toxicity of antidepressants: Rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010;196:354-8. [PUBMED] |
46. | Baranczyk-Kuzma A, Kuzma M, Gutowicz M, Kazmierczak B, Sawicki J. Glutathione S-transferase pi as a target for tricyclic antidepressants in human brain. Acta Biochim Pol 2004;51:207-12. |